This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

3 Feb 2014

Cytovance Biologics Breaks Ground on GMP Warehouse and Manufacturig Operations Facility

Cytovance Biologics, Inc., a leading full-service contract manufacturer of mammalian and microbial biologics, broke ground on an expansion facility to contain both manufacturing operations and GMP warehousing. The multi-million dollar capital investment project is being built by Capstone Construction and is expected to be completed by June 2014.


Cytovance is rapidly growing and expanding its capabilities in the areas of microbial, mammalian, and fill/finish operations with the addition of a new 1000-L Microbial Fermenter, an automated fill/finish machine, and a 2500-L stainless steel bioreactor.


The increase in scale and service offerings at the company's existing facilities identified the need to locate a new building to house our GMP warehousing and future manufacturing expansions. Cytovance selected a construction site 2 miles north of its current campus. The new facility located at 3500 N. Santa Fe will house 20,000 sq ft of climate controlled and monitored GMP warehouse space and 10,000 sq ft of dedicated space for existing and future manufacturing operations. Initially, this cleanroom space will be used for weighing and dispensing activities. 


“Our new GMP warehouse will support incoming and outgoing supply chain activities and provide full segregation between incoming, quarantine, and released materials,” explained Don Wuchterl, Senior Vice President of Manufacturing Operations. “The additional manufacturing space will provide Cytovance with future expansion space to quickly meet our clients’ contract manufacturing requirements.” 


In 2013, Cytovance Biologics was recognised as one of the fastest growing companies in Oklahoma City by the Greater Oklahoma City Chamber of Commerce. This expansion positions Cytovance to meet customer demands for both mammalian and microbial services. The company continues to provide analytical method development and process development for all phases of clinical trials and commercialisation. Cytovance offers regulatory expertise to support validation and commercial launch for therapeutic proteins, recombinant proteins and monoclonal antibodies.

Related News